75 completed, 9 unknown, 6 terminated, 1 withdrawn. 35 Phase 2, 22 Phase 4, 18 Phase 3, 4 Not applicable, 4 Phase 1.
Follow ledipasvir, sofosbuvir drug combination: new trials by email Literature Review of ledipasvir, sofosbuvir drug combination trials Research Report on ledipasvir, sofosbuvir drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19 Sofosbuvir and Ledipasvir, Nitazoxanide - COVID | Phase 4 | Completed | Assiut University | 240 | 2020-07-15 | 2020-11-12 |
| Metabolic Changes in Chronic HCV Patients Receiving DAAS sofosbuvir plus daclatasvir, Sofosbuvir plus Ledipasvir - Chronic Hepatitis C | Unknown | Ain Shams University | 100 | 2019-10-01 | 2020-01-02 | |
| Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI - Cardiovascular Diseases, Hepatitis C | Phase 4 | Completed | University of Maryland, Baltimore | 87 | 2018-11-18 | 2023-05-22 |
| Treatment of Egyptian Hepatitis C Genotype 4 Infected Children and Adolescents With Combined Ledipasvir/Sofosbuvir Combined therapy LDV and SOF - Hepatitis C Genotype 4 | Phase 4 | Unknown | Yassin Abdelghaffar Charity Center for Liver Disease and Research | 25 | 2018-08-01 | 2018-11-16 |
| PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders Sofosbuvir and Ledipasvir - HCV Infection, Beta Thalassemia Major | Phase 3 | Unknown | Ain Shams University | 24 | 2018-06-11 | 2023-03-06 |
| Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease. Ledipasvir/Sofosbuvir - Gaucher Disease, HCV | Phase 4 | Unknown | Mansoura University Children Hospital | 10 | 2018-04-03 | 2018-10-30 |
| Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet - Hepatitis C, Chronic | Phase 2 | Completed | Mansoura University Children Hospital | 50 | 2018-03-01 | 2021-10-25 |
| Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG - Hepatitis B | Phase 2 | Completed | University of Maryland, Baltimore | 21 | 2018-02-01 | 2021-09-20 |
| Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF - Hepatitis C, HIV Coinfection | Phase 4 | Completed | University of Colorado, Denver | 10 | 2018-01-08 | 2021-02-11 |
| The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia sofosbuvir daclatasvir, Ledipasvir/sofosbuvir - Hepatitis C | Not applicable | Unknown | Assiut University | 50 | 2017-11-01 | 2017-12-07 |
| Effect of Hepatitis C Clearance on Insulin Resistance Sofosbuvir 400 milligram, Daclatasvir 60 milligram, Ribavirin 400 milligram - Insulin Resistance, Hepatitis C | Phase 4 | Completed | Alexandria University | 160 | 2017-10-30 | 2020-07-07 |
| Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] - Beta-Thalassemia, Hepatitis C | Phase 4 | Completed | Tanta University | 50 | 2017-10-01 | 2019-05-23 |
| Harvoni Treatment Porphyria Cutanea Tarda Harvoni - Porphyria Cutanea Tarda, Hepatitis C | Phase 2 | Completed | Wake Forest University Health Sciences | 23 | 2017-09-06 | 2023-07-03 |
| Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Ledipasvir 90mg/Sofosubvir 400mg - Hematopoietic Stem Cell Transplantation | Phase 4 | Withdrawn | Kaiser Permanente | 2017-09-01 | 2018-08-31 | |
| Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma Ledipasvir and sofosbuvir - Indolent Lymphoma | Phase 2 | Unknown | National Taiwan University Hospital | 21 | 2017-09-01 | 2017-08-25 |
| Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease LDV/SOF - Hepatitis C Virus Infection | Phase 2 | Completed | Gilead Sciences | 95 | 2017-06-27 | 2020-03-02 |
| A Study of Sofosbuvir and Ledipasvir From Soviredia 90/400 mg Tablets (Minapharm, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA) Soviredia, Harvoni (first dose), Harvoni (Second dose) - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 30 | 2017-04-05 | 2019-07-31 |
| Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea LDV/SOF - Hepatitis C Virus | Completed | Gilead Sciences | 1081 | 2016-12-05 | 2021-11-29 | |
| Hepatitis C Virus(HCV) Heart and Lung Study Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) - Hepatitis C, Chronic, Heart Failure | Phase 4 | Completed | Duke University | 15 | 2016-12-01 | 2020-04-21 |
| Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs Harvoni (Fixed dose combination ledipasvir/sofosbuvir) - Hepatitis C | Phase 4 | Completed | Rockefeller University | 34 | 2016-11-15 | 2019-08-13 |
Showing 20 of 91. Sign in to see all of them.
Hepatitis C (56) · Hepatitis C, Chronic (23) · Liver Diseases (9) · Virus Diseases (6) · Fibrosis (5) · Hepatitis (5) · RNA Virus Infections (4) · Acquired Immunodeficiency Syndrome (3) · Digestive System Diseases (3) · Enterovirus Infections (3) · Flaviviridae Infections (3) · Hepatitis, Chronic (3) · Hepatitis, Viral, Human (3) · Picornaviridae Infections (3) · HIV Infections (2)
Gilead Sciences (37) · Humanity and Health Research Centre (5) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2) · Ain Shams University (2) · Assiut University (2) · Genuine Research Center, Egypt (2) · Mansoura University Children Hospital (2) · National Taiwan University Hospital (2) · Tanta University (2) · Third Affiliated Hospital, Sun Yat-Sen University (2) · University of Maryland, Baltimore (2) · ANRS, Emerging Infectious Diseases (1) · Alexandria University (1) · Catherine Chappell (1) · Duke University (1)
United States (40) · Egypt (15) · New Zealand (9) · Germany (8) · Canada (7) · France (7) · Italy (7) · Puerto Rico (7) · Australia (6) · China (6) · United Kingdom (6) · Spain (5) · Taiwan (4) · Austria (3) · Belgium (3)
Robert H Hyland, DPhil (3) · Ahmed Elshafeey, Ph.D. Pharma (2) · George Lau, MD (2) · Jenny Yang, PharmD (2) · Robert H. Hyland, DPhil (2) · Shampa De-Oertel, PhD (2) · Ahmed M Noaman, MD (1) · Aimable Mbituyumuremyi, MD (1) · Aisha El Sharkawy, MD (1) · Amandeep Sahota, MD (1) · Amr Maged (1) · Andrew Muir, MD (1) · Annie Luetkemeyer, MD (1) · Asem Elfert, Prof (1)
PMID 27553375, PMID 24209977, PMID 24720702, PMID 29091342, PMID 11413125, PMID 12450640, PMID 12618532, PMID 12823087, PMID 15560058, PMID 15637534, PMID 17695343, PMID 19897823, PMID 23059806, PMID 23281974, PMID 23300053, PMID 23607593, PMID 23607594, PMID 24067879, PMID 24262278, PMID 24428467, PMID 24725238, PMID 24725239, PMID 25773757, PMID 25846014, PMID 25985734, PMID 26196665, PMID 26261007, PMID 26280786, PMID 26743093, PMID 26803446, PMID 26841930, PMID 26891418, PMID 26907736, PMID 27198664, PMID 27225242, PMID 27240903, PMID 27351341, PMID 27367295, PMID 27842383, PMID 27917405, PMID 27959735, PMID 27997679, PMID 28137593, PMID 28329053, PMID 28397698, PMID 28535298, PMID 28567369, PMID 28785771, PMID 28957984, PMID 29174546
2014 (7), 2015 (2), UM1AI068636 (2), 2016 (1), R01DA033777 (1), U01AI115714 (1), U54DK083909 (1)